oxLDL in Diabetes Mellitus Patients and Disease Periodontal
- Conditions
- Type 2 Diabetes Mellitus With Periodontal Disease
- Interventions
- Procedure: Non-surgical periodontal treatment
- Registration Number
- NCT03198832
- Lead Sponsor
- Universidade Estadual Paulista Júlio de Mesquita Filho
- Brief Summary
Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters.
- Detailed Description
Periodontal disease (PD) and diabetes mellitus type 2 (DM2) have the same inflammatory etiopathogenesis and demonstrate a bidirectional relationship, for DM2 affects the severity of PD, and this may contribute to the overall inflammatory burden of the individual, influencing the natural course DM2. The aim of this study is to establish whether individuals with DM with or without chronic periodontitis have an increase in oxLDL and what is the influence of periodontal treatment in the reduction of oxLDL with consequent improvement in Diabetes Mellitus parameters. 44 patients will be divided into 2 groups: Diabetic Patients with Chronic Periodontitis (DM2DP) and Diabetic Patients without Chronic Periodontitis (DM2). The DM2DP group will receive periodontal debridement and DM2 group will be treated with supragingival scaling. Both groups receive board control every 3 months. At baseline, 3 and 6 months after treatment, will be held making the clinical periodontal parameters (plaque index, gingival index, probing depth, gingival recession relative clinical attachment level and Periodontal Inflamed Surface Area (PISA) index) and blood collection for assessment serum inflammatory markers (oxLDL, LDL, HDL, total cholesterol, triglyceride, Interleukin (IL) IL-6, IL-8, IL-10, Tumor Necrosis Factor (TNF-α) and CRP). Biochemical analyzes will be carried out by Z-scan technique. The data obtained before and after periodontal therapy will be analyzed using the Shapiro-Wilk test.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 44
- individuals older than 35 years with DM2 diagnosed for more than five years and HbA1c between 7% and 11%;
- be diagnosed with generalized chronic periodontitis: present at least 6 sites with periodontal pocket and loss of insertion above 5mm and two more bags with loss of insertion above 6mm;
- present at least 20 teeth;
- agree to participate in the study and sign the informed consent form
- patients with cardiovascular diseases, cancer, gastrointestinal disorders, skin diseases, pregnancy, lactation, smoking, arthritis, lupus or other diseases of inflammatory origin;
- have undergone periodontal treatment in the last 12 months;
- have made use of antioxidant supplements, anti-inflammatories, or antibiotics within the previous 3 months;
- make use of medications that can alter the marking and concentration of oxLDL, for example, statins;
- have changed the medication for glycemic control in the last 3 months;
- present dental elements with pulpal or periapical inflammation.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Arm && Interventions
Group Intervention Description Type 2 diabetes mellitus and periodontitis Non-surgical periodontal treatment periodontal debridement in a single session.
- Primary Outcome Measures
Name Time Method Probing depth change baseline, 90 and 180 days The change in the probing depth will be measure in millimeters before and after the treatment.
- Secondary Outcome Measures
Name Time Method oxLDL concentration Change baseline and 180 days Change in concentration of oxLDL will be measured before and treatment.
LDL, HDL, Total cholesterol, Triacylglycerol baseline and 180 days Blood concentration (g/ml) will be measured before and after periodontal therapy.
Gingival Recession baseline, 90 and 180 days Evaluated in millimeters before and after the treatment.
Clinical Attachment Level baseline, 90 and 180 days Evaluated in millimeters before and after the treatment.
Plaque index baseline, 90 and 180 days Number of teeth affected before and after periodontal treatment
Gingival index baseline, 90 and 180 days number of teeth affected before and after periodontal treatment